Fish oil Inhibition of Stenosis in Haemodialysis grafts study
- Conditions
- End Stage Renal Disease (ESRD)Urological and Genital DiseasesRenal disease
- Registration Number
- ISRCTN15838383
- Lead Sponsor
- Canadian Institutes of Health Research (CIHR) (Canada)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 232
1. End stage renal disease haemodialysis patients who require a graft access
2. 18 and above years of age, either sex
1. Acute renal failure, likely to be reversible with recovery of renal function
2. Surgical revision of a previous access e.g. a jump graft (i.e. must be a new PTFE graft)
3. Pregnancy
4. Active malignancy
5. Active major bleed within one month of enrolment (see below for definition of major bleed)
6. Malignant hypertension
7. Receiving more than two anti-platelet agents or anticoagulants i.e. use of Acetylsalicylic Acid (ASA) and coumadin is not an exclusion
8. Life expectancy less than six months
9. PTFE grafts that fail prior to and including post-operative day seven
10. Involvement in another graft trial
11. Current fish oil ingestion at the time of randomisation
12. Any known allergy to fish or fish products
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of PTFE grafts with loss of native patency within 12 months
- Secondary Outcome Measures
Name Time Method